Q&A Genmab 2021-03-23

	23/3 15:34 af Jan Van de Winkel	We expect our 2021 revenue to be in the range of 6.8 to 7.5 billion kroner..
	23/3 15:34 af Jan Van de Winkel	Operating income was 6.3 billion compared to 2.6 billion in 2019..
	23/3 15:33 af Jan Van de Winkel	Total expenses were approximately 3.8 billion, with 83% being R&D and 17% G&A..
	23/3 15:33 af Jan Van de Winkel	The increase was primarily driven by the upfront payment from AbbVie and higher DARZALEX royalties..
	23/3 15:33 af Jan Van de Winkel	2020 is our 8th year of profitability with an impressive 139% increase in operating profit vs 2019. In 2020, revenue came in at 10.1 billion Kroner, an increase of over 4.7 billion compared to 2019..
	23/3 15:33 af Jan Van de Winkel	Financial highlights:..
	23/3 15:32 af Jan Van de Winkel	These events, in addition to the advancement of epcoritamab into Phase 3, underscore the potential of our DuoBody® technology platform to create innovative and differentiated antibody therapeutics..
	23/3 15:32 af Jan Van de Winkel	It is also worth noting that Janssen submitted applications for approval for amivantamab in both the U.S. and in Europe in December. These are the first regulatory submissions for a product candidate that was created using Genmab’s proprietary DuoBody® technology platform. Amivantamab is also the first DuoBody® to receive Breakthrough Therapy Designation (BTD) from the U.S. FDA..
	23/3 15:31 af Jan Van de Winkel	A third Genmab-created antibody was approved in 2020, with the U.S. Food and Drug Administration approval of TEPEZZA® (teprotumumab), developed and commercialized by Horizon Therapeutics, for thyroid eye disease (TED). TEPEZZA® is the first and only U.S. FDA approved medicine for the treatment of TED, and it has had an incredibly successful launch, despite the impact of COVID-19..
	23/3 15:31 af Jan Van de Winkel	An additional highly anticipated approval in 2020 was that of subcutaneous ofatumumab, as Kesimpta®, in the U.S. for relapsing forms of multiple sclerosis. Kesimpta®, which is being developed and marketed by Novartis, is the first B-cell therapy that can be self-administered by patients at home, using the Sensoready® autoinjector pen, once monthly after starting therapy..
	23/3 15:30 af Jan Van de Winkel	In addition to the development of our own pipeline, there were great leaps forward with antibodies created by Genmab that are now being developed and marketed by other companies. DARZALEX® has already revolutionized the treatment of multiple myeloma, and in 2020 it became the first and only subcutaneously administered CD38 antibody approved in the world..
	23/3 15:30 af Jan Van de Winkel	These are among the many milestones for Genmab that we have reached over the past 12 months..
	23/3 15:29 af Jan Van de Winkel	Recent highlights include the initiation of the first phase 3 trials with epcoritamab and tisotumab vedotin as well as the BLA submission for tisotumab vedotin, the first for a product where Genmab has 50% ownership of the program. If approved, tisotumab vedotin would be a first-in-class therapy and we believe it has the potential to become an important treatment option for women with recurrent or metastatic cervical cancer, who have disease progression on or after chemotherapy..
	23/3 15:29 af Helge Larsen/PI-redaktør	First of all let me congratulate on the great results for 2020. Can you give us a short-term update on key figures and important events?
	23/3 15:28 af Helge Larsen/PI-redaktør	Good afternoon Jan van de Winkel. Welcome to Q&A here on ProInvestor.com. We are very happy to have you back here and ready to answer questions from our investors.
	23/3 15:28 af Jan Van de Winkel	Hello all, Thank you for inviting us again to talk with you all. We look forward to an energizing discussion with lots of clever questions as usual.
	22/3 16:39 af Helge Larsen/PI-redaktør	Denne Q&A afholdes tirsdag d. 23 marts kl. 15,30.